## Sanjay Kalra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9461462/publications.pdf Version: 2024-02-01



SANIAV KALDA

#	Article	IF	CITATIONS
1	CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, , 1-7.	1.7	3
2	Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 517-526.	1.7	13
3	Validating Automatic Diadochokinesis Analysis Methods Across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research, 2022, 65, 940-953.	1.6	7
4	Longitudinal surface-based spatial Bayesian GLM reveals complex trajectories of motor neurodegeneration in ALS. NeuroImage, 2022, , 119180.	4.2	1
5	Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis. Human Brain Mapping, 2022, 43, 1519-1534.	3.6	7
6	Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States. PLoS ONE, 2022, 17, e0269154.	2.5	8
7	Neuroanatomical associations of the Edinburgh cognitive and Behavioural ALS screen (ECAS). Brain Imaging and Behavior, 2021, 15, 1641-1654.	2.1	11
8	Amide signal intensities may be reduced in the motor cortex and the corticospinal tract of ALS patients. European Radiology, 2021, 31, 1401-1409.	4.5	4
9	The Canadian Neuromuscular Disease Registry 2010–2019: A Decade of Facilitating Clinical Research Througha Nationwide, Pan-NeuromuscularDisease Registry. Journal of Neuromuscular Diseases, 2021, 8, 53-61.	2.6	15
10	MRI Texture Analysis Reveals Brain Abnormalities in Medically Refractory Trigeminal Neuralgia. Frontiers in Neurology, 2021, 12, 626504.	2.4	4
11	Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, e803-e813.	1.1	12
12	Genetic testing for amyotrophic lateral sclerosis in Canada – an assessment of current practices. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-8.	1.7	9
13	Lung volume recruitment improves volitional airway clearance in amyotrophic lateral sclerosis. Muscle and Nerve, 2021, 64, 676-682.	2.2	4
14	Mixed pathologies mimicking motor neuron disease: a case report and review of the literature. Folia Neuropathologica, 2021, 59, 403-408.	1.2	0
15	Reliability of 3D texture analysis: A multicenter MRI study of the brain. Journal of Magnetic Resonance Imaging, 2020, 51, 1200-1209.	3.4	17
16	Texture classification of MR images of the brain in ALS using M-CoHOG: A multi-center study. Computerized Medical Imaging and Graphics, 2020, 79, 101659.	5.8	12
17	Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study. NeuroImage: Clinical, 2020, 28, 102385.	2.7	25
18	Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43. Brain Communications, 2020, 2, fcaa061.	3.3	22

SANJAY KALRA

#	Article	IF	CITATIONS
19	A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS. Neurology, 2020, 95, e943-e952.	1.1	45
20	Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. Cmaj, 2020, 192, E1453-E1468.	2.0	44
21	Reliability and validity of speech & pause measures during passage reading in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 42-50.	1.7	26
22	Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 246-251.	1.7	6
23	Bing–Neel Syndrome Mimicking Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 2020, 47, 419-421.	0.5	0
24	Magnetic Resonance Spectroscopy in ALS. Frontiers in Neurology, 2019, 10, 482.	2.4	37
25	Cerebral degeneration in amyotrophic lateral sclerosis. Neurology: Clinical Practice, 2019, 9, 400-407.	1.6	13
26	Quantifying changes on susceptibility weighted images in amyotrophic lateral sclerosis using MRI texture analysis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 396-403.	1.7	10
27	Corticospinal tract degeneration in ALS unmasked in T1â€weighted images using texture analysis. Human Brain Mapping, 2019, 40, 1174-1183.	3.6	22
28	Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 2018, 45, 652-659.	0.5	15
29	Evaluating the cerebral correlates of survival in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1350-1361.	3.7	19
30	Alzheimer's disease: 3â€Dimensional MRI texture for prediction of conversion from mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 755-763.	2.4	39
31	Texture Analysis to Detect Cerebral Degeneration in Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 2018, 45, 533-539.	0.5	7
32	Utility of the Addenbrooke's Cognitive Examination in Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 2018, 45, 527-532.	0.5	5
33	White matter structural network abnormalities underlie executive dysfunction in amyotrophic lateral sclerosis. Human Brain Mapping, 2017, 38, 1249-1268.	3.6	22
34	Hair product artifact in magnetic resonance imaging. Magnetic Resonance Imaging, 2017, 35, 1-3.	1.8	7
35	Cerebral Degeneration in Amyotrophic Lateral Sclerosis Revealed by 3-Dimensional Texture Analysis. Frontiers in Neuroscience, 2016, 10, 120.	2.8	25
36	Fatigue in Multiple Sclerosis: Assessing Pontine Involvement Using Proton MR Spectroscopic Imaging. PLoS ONE, 2016, 11, e0149622.	2.5	16

SANJAY KALRA

#	Article	IF	CITATIONS
37	Investigating Default Mode and Sensorimotor Network Connectivity in Amyotrophic Lateral Sclerosis. PLoS ONE, 2016, 11, e0157443.	2.5	85
38	A REVIEW OF TEXTURE CLASSIFICATION METHODS AND THEIR APPLICATIONS IN MEDICAL IMAGE ANALYSIS OF THE BRAIN. , 2016, , 351-369.		1
39	Voxel-Based Texture Analysis of the Brain. PLoS ONE, 2015, 10, e0117759.	2.5	45
40	Robust Edge Aware Descriptor for Image Matching. Lecture Notes in Computer Science, 2015, , 553-568.	1.3	2
41	Robust Volumetric Texture Classification of Magnetic Resonance Images of the Brain Using Local Frequency Descriptor. IEEE Transactions on Image Processing, 2014, 23, 4625-4636.	9.8	18
42	Screening for frontal lobe and general cognitive impairment in patients with amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2014, 336, 191-196.	0.6	48
43	Diagnostic Accuracy of Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis. Academic Radiology, 2013, 20, 1099-1106.	2.5	70
44	Rotation Invariant Local Frequency Descriptors for Texture Classification. IEEE Transactions on Image Processing, 2013, 22, 2409-2419.	9.8	37
45	Noise robust rotation invariant features for texture classification. Pattern Recognition, 2013, 46, 2103-2116.	8.1	51
46	The effects of lung volume recruitment on coughing and pulmonary function in patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 111-115.	1.7	30
47	Familial amyotrophic lateral sclerosis in Alberta, Canada. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 273-277.	1.7	10
48	The CNDR: Collaborating to Translate New Therapies for Canadians. Canadian Journal of Neurological Sciences, 2013, 40, 698-704.	0.5	16
49	Establishing a Canadian Registry of Patients with Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 2013, 40, 29-35.	0.5	11
50	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 400-403.	10.2	156
51	Degeneration of the Mid-Cingulate Cortex in Amyotrophic Lateral Sclerosis Detected In Vivo with MR Spectroscopy. American Journal of Neuroradiology, 2011, 32, 403-407.	2.4	26
52	Mesial Prefrontal Cortex Degeneration in Amyotrophic Lateral Sclerosis: A High-Field Proton MR Spectroscopy Study. American Journal of Neuroradiology, 2011, 32, 1677-1680.	2.4	18
53	Inclusion Body Myositis Masquerading as Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 2010, 37, 687-691.	0.5	3
54	EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. European Journal of Neurology, 2010, 17, 526.	3.3	75

SANJAY KALRA

#	Article	IF	CITATIONS
55	Combined structural and neurochemical evaluation of the corticospinal tract in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 157-165.	2.1	48
56	Measurement of glutathione in human brain at 3T using an improved double quantum filter in vivo. Journal of Magnetic Resonance, 2009, 198, 160-166.	2.1	14
57	Measurement of glycine in human brain by triple refocusing <sup>1</sup> Hâ€MRS in vivo at 3.0T. Magnetic Resonance in Medicine, 2008, 59, 59-64.	3.0	32
58	Motor Cortex and Spinal Degeneration in Multisystem Atrophy: A Multimodal Study. Canadian Journal of Neurological Sciences, 2008, 35, 658-660.	0.5	1
59	Measurement of GABA and contaminants in gray and white matter in human brain in vivo. Magnetic Resonance in Medicine, 2007, 58, 27-33.	3.0	35
60	Spatial Profiling of the Corticospinal Tract in Amyotrophic Lateral Sclerosis Using Diffusion Tensor Imaging. Journal of Neuroimaging, 2007, 17, 234-240.	2.0	40
61	Detection of Cerebral Degeneration in Amyotrophic Lateral Sclerosis Using High-Field Magnetic Resonance Spectroscopy. Archives of Neurology, 2006, 63, 1144.	4.5	84
62	Unilateral Atrophy of Fungiform Papillae Associated with Lingual Nerve Injury. Canadian Journal of Neurological Sciences, 2006, 33, 428-429.	0.5	1
63	Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. Journal of Neurology, 2006, 253, 1060-1063.	3.6	49
64	Proton spectral editing for discrimination of lactate and threonine 1.31 ppm resonances in human brain in vivo. Magnetic Resonance in Medicine, 2006, 56, 660-665.	3.0	29
65	T2 measurement and quantification of glutamate in human brain in vivo. Magnetic Resonance in Medicine, 2006, 56, 971-977.	3.0	77
66	Uncontrollable movements in patient with diabetes mellitus. Cmaj, 2006, 175, 871-871.	2.0	9
67	Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1253-1255.	1.9	37
68	Magnetic Resonance Spectroscopy for Monitoring Neuronal Integrity in Amyotrophic Lateral Sclerosis. , 2006, 576, 275-282.		8
69	MRS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 111-114.	1.2	12
70	Neuroimaging in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 243-248.	1.2	29
71	A prospective, randomized, placeboâ€controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation	1.2	81
72	A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 22-26.	1.2	2

#	Article	IF	CITATIONS
73	Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. American Journal of Neuroradiology, 2003, 24, 476-80.	2.4	40
74	Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. NeuroReport, 1998, 9, 1757-1761.	1.2	179